Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Chronic myelogenous leukemia was once the most common indication for unrelated allogeneic hematopoietic stem cell transplantation but has become dramatically less so during the past 5 years. This procedure remains an option in chronic myelogenous leukemia but its use will become more sparing and selective. This review describes these trends and identifies the current role of the procedure in chronic myelogenous leukemia. RECENT FINDINGS: Allogeneic hematopoietic stem cell transplantation was the goal in chronic myelogenous leukemia for over 20 years and remains an option. Emergence of imatinib mesylate and other, second-generation tyrosine kinase inhibitors has transformed the landscape of transplantation in this setting. Treatment algorithms have been rewritten and, despite advances in hematopoietic stem cell transplantation (e.g. improved supportive care, decreased toxicity and reduced intensity conditioning), transplantation worldwide has declined. Additionally, the near universal exposure to imatinib mesylate or other kinase inhibitors before transplant consideration has increased expectations regarding outcomes after transplantation. SUMMARY: This review summarizes the history of transplantation for chronic myelogenous leukemia and defines the new natural history for this leukemia in the tyrosine kinase inhibitor era. Ultimately, enhanced understanding of the appropriate role of transplantation in these patients will lead to the best long-term outcomes.

Original languageEnglish (US)
Pages (from-to)127-133
Number of pages7
JournalCurrent Opinion in Hematology
Volume15
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Hematopoietic Stem Cell Transplantation
Transplants
Transplantation
Transplantation Conditioning
Natural History
Leukemia
Phosphotransferases
History
Imatinib Mesylate
Therapeutics

Keywords

  • Chronic myelogenous leukemia
  • Hematopoietic stem cell transplantation
  • Imatinib mesylate
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? / Maziarz, Richard.

In: Current Opinion in Hematology, Vol. 15, No. 2, 03.2008, p. 127-133.

Research output: Contribution to journalArticle

@article{5e159eb1f26d49da8254ca331209d49d,
title = "Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?",
abstract = "PURPOSE OF REVIEW: Chronic myelogenous leukemia was once the most common indication for unrelated allogeneic hematopoietic stem cell transplantation but has become dramatically less so during the past 5 years. This procedure remains an option in chronic myelogenous leukemia but its use will become more sparing and selective. This review describes these trends and identifies the current role of the procedure in chronic myelogenous leukemia. RECENT FINDINGS: Allogeneic hematopoietic stem cell transplantation was the goal in chronic myelogenous leukemia for over 20 years and remains an option. Emergence of imatinib mesylate and other, second-generation tyrosine kinase inhibitors has transformed the landscape of transplantation in this setting. Treatment algorithms have been rewritten and, despite advances in hematopoietic stem cell transplantation (e.g. improved supportive care, decreased toxicity and reduced intensity conditioning), transplantation worldwide has declined. Additionally, the near universal exposure to imatinib mesylate or other kinase inhibitors before transplant consideration has increased expectations regarding outcomes after transplantation. SUMMARY: This review summarizes the history of transplantation for chronic myelogenous leukemia and defines the new natural history for this leukemia in the tyrosine kinase inhibitor era. Ultimately, enhanced understanding of the appropriate role of transplantation in these patients will lead to the best long-term outcomes.",
keywords = "Chronic myelogenous leukemia, Hematopoietic stem cell transplantation, Imatinib mesylate, Tyrosine kinase inhibitors",
author = "Richard Maziarz",
year = "2008",
month = "3",
doi = "10.1097/MOH.0b013e3282f428ac",
language = "English (US)",
volume = "15",
pages = "127--133",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

AU - Maziarz, Richard

PY - 2008/3

Y1 - 2008/3

N2 - PURPOSE OF REVIEW: Chronic myelogenous leukemia was once the most common indication for unrelated allogeneic hematopoietic stem cell transplantation but has become dramatically less so during the past 5 years. This procedure remains an option in chronic myelogenous leukemia but its use will become more sparing and selective. This review describes these trends and identifies the current role of the procedure in chronic myelogenous leukemia. RECENT FINDINGS: Allogeneic hematopoietic stem cell transplantation was the goal in chronic myelogenous leukemia for over 20 years and remains an option. Emergence of imatinib mesylate and other, second-generation tyrosine kinase inhibitors has transformed the landscape of transplantation in this setting. Treatment algorithms have been rewritten and, despite advances in hematopoietic stem cell transplantation (e.g. improved supportive care, decreased toxicity and reduced intensity conditioning), transplantation worldwide has declined. Additionally, the near universal exposure to imatinib mesylate or other kinase inhibitors before transplant consideration has increased expectations regarding outcomes after transplantation. SUMMARY: This review summarizes the history of transplantation for chronic myelogenous leukemia and defines the new natural history for this leukemia in the tyrosine kinase inhibitor era. Ultimately, enhanced understanding of the appropriate role of transplantation in these patients will lead to the best long-term outcomes.

AB - PURPOSE OF REVIEW: Chronic myelogenous leukemia was once the most common indication for unrelated allogeneic hematopoietic stem cell transplantation but has become dramatically less so during the past 5 years. This procedure remains an option in chronic myelogenous leukemia but its use will become more sparing and selective. This review describes these trends and identifies the current role of the procedure in chronic myelogenous leukemia. RECENT FINDINGS: Allogeneic hematopoietic stem cell transplantation was the goal in chronic myelogenous leukemia for over 20 years and remains an option. Emergence of imatinib mesylate and other, second-generation tyrosine kinase inhibitors has transformed the landscape of transplantation in this setting. Treatment algorithms have been rewritten and, despite advances in hematopoietic stem cell transplantation (e.g. improved supportive care, decreased toxicity and reduced intensity conditioning), transplantation worldwide has declined. Additionally, the near universal exposure to imatinib mesylate or other kinase inhibitors before transplant consideration has increased expectations regarding outcomes after transplantation. SUMMARY: This review summarizes the history of transplantation for chronic myelogenous leukemia and defines the new natural history for this leukemia in the tyrosine kinase inhibitor era. Ultimately, enhanced understanding of the appropriate role of transplantation in these patients will lead to the best long-term outcomes.

KW - Chronic myelogenous leukemia

KW - Hematopoietic stem cell transplantation

KW - Imatinib mesylate

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=40049112250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049112250&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e3282f428ac

DO - 10.1097/MOH.0b013e3282f428ac

M3 - Article

VL - 15

SP - 127

EP - 133

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -